Iris Energy Limited vs Mesoblast Limited — how do they compare? Iris Energy Limited trades at $36.65 (market cap $14.07B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Iris Energy Limited is far larger — about 8× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 54,492,460). Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and Mesoblast Limited for 14 Days on average.
| IREN | MESO | |
|---|---|---|
Market Cap | $14.07B | $1.75B |
Volume | 54,492,460 | 239,027 |
Sector | Technology | Health |
52-Week High | $76.41 | $20.96 |
52-Week Low | $29.31 | $13.19 |
Typical Hold Time | 28 Days | 14 Days |
Enterprise Value | $16.02B | $1.83B |
Signals from Pluang's Aura AI — not financial advice
IREN trades at $38.69, down 6.27% today, amid a bearish technical trend and recent earnings misses. The company is aggressively pivoting from Bitcoin mining to AI infrastructure, securing multi-billion dollar contracts, but faces ballooning losses with a net income margin of -99.38% in 2026. Analyst consensus remains strongly bullish with a $81 price target, highlighting long-term revenue potential from AI demand, yet near-term execution and profitability challenges weigh on investor sentiment.
Outlook hinges on successful execution of AI expansion and cost management; opportunities include massive contracted revenue growth, but risks involve high capital burn, intense competition, and persistent negative earnings. The stock offers significant upside if targets are met, but volatility is expected amid transformative shifts.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →